搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
verywellhealth
1 天
Does Sleep Apnea Cause Hypertension?
Sleep apnea, or specifically obstructive sleep apnea (OSA), is linked to hypertension (high blood pressure). OSA affects 30% ...
Managed Healthcare Executive
1 天
The Need to Enhance Diagnosis and Treatment for Pulmonary Hypertension-ILD Patients Across ...
Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.
Pulmonaryhypertensionnews.com
4 天
After 25 years, I’m still absorbing lessons from chronic illness
Columnist Anna Jeter was recently reminded that she's still absorbing lessons from her chronic illness after 25 years of ...
4 天
Is shortness of breath during everyday activities a warning sign of pulmonary hypertension?
Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...
Managed Healthcare Executive
5 天
Patients with PAH Who Get Sepsis Experience Care Differences
New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.
The American Journal of Managed Care
5 天
2025 GOLD Report: New Insights on COPD Risks, Management
The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk ...
pharmaphorum
6 天
MSD adds rocket fuel to Winrevair's engine in PAH
In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...
BioPharma Dive
7 天
New data could help Merck expand use of cardiovascular drug
Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...
Business Wire
7 天
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met ...
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...
7 天
Pulmonary Arterial Hypertension Market Is Expected To Reach Revenue Of USD 13.2 Bn By 2033 ...
Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...
7 天
Merck's therapy for rare lung condition shown to help reduce risk of death in study
Winrevair was approved to treat pulmonary arterial hypertension (PAH), a progressive disorder caused by a constriction of ...
Le Lézard
7 天
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIRtm (sotatercept-csrk) Met ...
Merck , known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈